Senseonics Stock Price, News & Analysis

Senseonics Holdings (NYSE: SENS) has submitted a CE Mark registration for its Eversense 365 CGM system, the world's first one-year continuous glucose monitoring system. The device, already FDA-approved and launched in the US in October 2024, could soon be commercialized across EU member countries through Ascensia Diabetes Care.

The Eversense 365 system offers significant advantages over traditional short-term CGMs, including: year-long duration, removable smart transmitter, trusted alerts with exceptional accuracy, comfortable silicone-based adhesives, and weekly calibration requirements. Following CE Mark approval, the company plans distribution in Germany, Italy, Spain, Poland, Switzerland, and Sweden.

The system is cleared in the US as an integrated CGM (iCGM) system, compatible with insulin pumps for automated insulin delivery (AID) systems, with ongoing partnership discussions with pump manufacturers.

Senseonics Holdings (NYSE: SENS) announced preliminary Q4 2024 revenue of $8.3 million and full-year revenue of $22.5 million. The company reported significant growth following the FDA approval and launch of Eversense® 365, their implantable continuous glucose monitoring system.

Key achievements include a 56% increase in global patient base to 6,000, reaching over 1,000 U.S. prescribers in 2024. Post-launch indicators show doubled Direct to Consumer leads in Q4, record-high monthly patient shipments of 600 in December, and a 49% increase in patients switching from competitors. The company maintained approximately $74.9 million in cash and equivalents as of December 31, 2024.

Senseonics canceled its planned Special Meeting for a reverse stock split, citing recent share price appreciation. The company expects positive revenue growth in 2025, with detailed guidance to be provided with full fiscal year 2024 results.

Senseonics Holdings (NYSE: SENS) reported strong early performance indicators for its Eversense 365 launch, which began shipping in November. Key highlights include: doubled Direct-to-Consumer leads in October and November compared to pre-launch months, highest new patient shipments since Ascensia partnership began, 42% increase in prescribing providers, and 69% increase in prescriptions from top prescribers.

The company maintains its target of 50% annual growth in patient installed base for 2024 and reiterates global net revenue guidance of approximately $22 million. One-third of Eversense 365 prescribers are first-time users, and patient switches from competitive CGMs have increased 47% since launch. The company plans a reverse stock split in January 2025 to enhance appeal to institutional investors.

Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its participation in two upcoming investor conferences in November. The company will present at the Stifel 2024 Healthcare Conference on November 19, delivering a corporate overview and holding one-on-one meetings, with a presentation scheduled for 9:10 am ET. Additionally, management will participate in the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 21, conducting one-on-one meetings. Both events will be accessible via webcast through the company's investor relations website.

Senseonics Holdings reported Q3 2024 financial results with total revenue of $4.3 million, down from $6.1 million in Q3 2023. The company announced FDA approval for Eversense 365, the world's first 365-day CGM system. Q3 net loss was $24.0 million ($0.04 per share). The company raised over $20 million from equity offerings and implemented restructuring targeting $10M cost reduction in 2025. Full-year 2024 global revenue guidance is approximately $22 million. Cash position stood at $74.8 million with $55.9 million in debt as of September 30, 2024.

Senseonics Holdings (NYSE American: SENS) has announced a $16 million registered direct offering of 45,714,286 common stock shares at $0.35 per share. The company will also issue unregistered warrants to purchase an additional 45,714,286 shares at $0.35 per share in a concurrent private placement. The warrants will be exercisable after six months and expire after five years, potentially generating an additional $16 million if fully exercised. The proceeds will be used for working capital, general corporate purposes, and potentially repaying borrowings on 5.25% Convertible Senior Notes due 2025. The offering is expected to close around October 28, 2024.

Senseonics Holdings (NYSE American: SENS), a medical technology company developing long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its upcoming third quarter 2024 financial results release. The results will be disclosed after market close on Thursday, November 7, 2024, followed by a conference call at 4:30 p.m. Eastern Time. Investors can access the webcast through the company's website or join via phone using the provided dial-in numbers.

Senseonics Holdings (NYSE American: SENS) announced a virtual KOL event on October 25, 2024, at 11:00am ET to discuss the Eversense® 365 Continuous Glucose Monitoring (CGM) system. This next-generation system, recently cleared by the FDA for people with Type 1 and Type 2 diabetes aged 18 and older, is the world's first one-year CGM system.

The event will feature Dr. David T. Ahn from Hoag Medical Group and Dr. Jeff Ciaramita from Mercy health system, along with company management. They will highlight Eversense 365 in clinical practice and provide an overview of Senseonics' commercial collaboration with Mercy. A live Q&A session will follow the presentations.

Senseonics Holdings, Inc. (NYSE American: SENS) and Mercy healthcare system have announced the first commercial use of the Eversense 365 CGM system, the world's only continuous glucose monitor providing one year of accurate monitoring with minimal interruptions. This milestone marks the beginning of the commercial launch managed by Ascensia Diabetes Care.

Eversense 365, recently approved by the FDA, offers patients with Type 1 and Type 2 diabetes aged 18 and older a differentiated CGM experience, requiring only one sensor replacement per year and one calibration per week. Mercy, serving 3 million patients annually, estimates that about 30,000 of its patients could benefit from this technology.

The long-term monitoring solution aims to improve glycemic control, reduce diabetes-related distress, and lower overall healthcare costs. Senseonics and Mercy expect this breakthrough to enhance the quality of care while reducing costs for providers and payers.